ANTONIETA ACOSTA: Open Payments
NPI 1023399698 · CLOVIS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,776 in 98 payments from 21 companies in 2025. Trend: 2023 $3,269 · 2024 $3,422 · 2025 $2,776
Food & beverage: $2,776
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 13 | $637 |
| Novo Nordisk Inc | 17 | $469 |
| ABBVIE INC. | 13 | $392 |
| Xeris Pharmaceuticals, Inc. | 15 | $261 |
| AstraZeneca Pharmaceuticals LP | 8 | $227 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $157 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $117 |
| Amgen Inc. | 5 | $90 |
| Lilly USA, LLC | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
Products named: Korlym, VRAYLAR, Ozempic, RECORLEV, FARXIGA, CAPLYTA, JARDIANCE, Wegovy.
Industry payments across CA — which companies pay providers there.
